This study showed that 64Cu-SAR-bisPSMA is effective in detecting lesions in PC patients with BCR, who had a negative or equivocal SOC scan at study entry.
More lesions and more participants with a positive scan were identified earlier by 64Cu-SAR-bisPSMA vs. SOC PSMA imaging.
Results indicate that 64Cu-SAR-bisPSMA is able to identify lesions from 29 days to more than 6 months earlier than SOC PSMA agents.
Lesions <5 mm in diameter were identified by 64Cu-SAR-bisPSMA in 14% of participants.
These findings have important clinical implications as the early identification of lesions in BCR patients can inform different treatment pathways. ..."
CU6 Price at posting:
$1.81 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)